9.28
-0.02 (-0.22%)
| Previous Close | 9.30 |
| Open | 9.43 |
| Volume | 726,882 |
| Avg. Volume (3M) | 1,064,045 |
| Market Cap | 598,333,568 |
| Price / Earnings (Forward) | 12.14 |
| Price / Sales | 1.72 |
| Price / Book | 53.71 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -20.40% |
| Operating Margin (TTM) | -19.00% |
| Diluted EPS (TTM) | -0.890 |
| Quarterly Revenue Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 2,353.84% |
| Current Ratio (MRQ) | 2.34 |
| Operating Cash Flow (TTM) | -23.02 M |
| Levered Free Cash Flow (TTM) | -9.39 M |
| Return on Assets (TTM) | -9.36% |
| Return on Equity (TTM) | -949.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Evolus, Inc. Common Stock | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 5.46% |
| % Held by Institutions | 85.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Needham, 137.07%) | Hold |
| Median | 20.00 (115.52%) | |
| Low | 18.00 (BTIG, 93.97%) | Buy |
| Average | 20.00 (115.52%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 6.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 08 Sep 2025 | 18.00 (93.97%) | Buy | 7.61 |
| 06 Aug 2025 | 18.00 (93.97%) | Buy | 6.37 | |
| HC Wainwright & Co. | 06 Aug 2025 | 20.00 (115.52%) | Buy | 6.37 |
| Needham | 06 Aug 2025 | 22.00 (137.07%) | Hold | 6.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Sep 2025 | Announcement | Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer |
| 25 Aug 2025 | Announcement | Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp |
| 08 Aug 2025 | Announcement | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 31 Jul 2025 | Announcement | Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins |
| 22 Jul 2025 | Announcement | Evolus to Report Second Quarter Financial Results on August 5, 2025 |
| 11 Jul 2025 | Announcement | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 09 Jul 2025 | Announcement | Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France |
| 13 Jun 2025 | Announcement | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |